Research & Literature

Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.

Andersson H, Sem M, Lund MB, et al.

Rheumatology (Oxford, England) 2015; (54(8)):1420-8 doi:10.1093/rheumatology/kev004.

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.

Fischer A, Antoniou KM, Brown KK, et al.

The European respiratory journal 2015; (46(4)):976-87 doi:10.1183/13993003.00150-2015.

Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.

Xu Y, Yang CS, Li YJ, et al.

Clinical rheumatology 2016; (35(1)):113-6 doi:10.1007/s10067-015-3139-z.

Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease.

Lee JS, Fischer A

Expert review of clinical immunology 2016; (12(5)):509-20 doi:10.1586/1744666X.2016.1139454.

Patients With Fibrotic Interstitial Lung Disease Hospitalized for Acute Respiratory Worsening: A Large Cohort Analysis.

Moua T, Westerly BD, Dulohery MM, et al.

Chest 2016; (149(5)):1205-14.

Interstitial pneumonia with autoimmune features: a critical appraisal of the new definition.

Strek ME, Costabel U

Current opinion in pulmonary medicine 2016; (22(5)):442-9 doi:10.1097/MCP.0000000000000298.

Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease.

Oldham JM, Lee C, Valenzi E, et al.

Respiratory medicine 2016; (121()):117-122 doi:10.1016/j.rmed.2016.11.007.

Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II.

Tashkin DP, Volkmann ER, Tseng CH, et al.

Chest 2017; (151(4)):813-820 doi:10.1016/j.chest.2016.11.052.

Anti-Citrullinated Protein Antibodies Are Associated With Neutrophil Extracellular Traps in the Sputum in Relatives of Rheumatoid Arthritis Patients.

Demoruelle MK, Harrall KK, Ho L, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2017; (69(6)):1165-1175 doi:10.1002/art.40066.

Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF).

Jee AS, Adelstein S, Bleasel J, et al.

Journal of clinical medicine 2017; (6(5)) doi:10.3390/jcm6050051.

Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis.

Kondoh Y, Cottin V, Brown KK

European respiratory review : an official journal of the European Respiratory Society 2017; (26(145)) doi:10.1183/16000617.0050-2017.

Palliative care in interstitial lung disease: living well.

Kreuter M, Bendstrup E, Russell AM, et al.

The Lancet. Respiratory medicine 2017; (5(12)):968-980 doi:10.1016/S2213-2600(17)30383-1.

[Clinical and radiological features of adult patients with different antisynthetase syndrome based on serum anti-aminoacyl-tRNA synthetase antibody type].

Li S, Huang H, Song XY, et al.

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2017; (40(12)):919-924 doi:10.3760/cma.j.issn.1001-0939.2017.12.011.

Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial.

Visca D, Mori L, Tsipouri V, et al.

The Lancet. Respiratory medicine 2018; (6(10)):759-770 doi:10.1016/S2213-2600(18)30289-3.

Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population.

Fu Q, Wang L, Li L, et al.

Clinical rheumatology 2019; (38(4)):1109-1116 doi:10.1007/s10067-018-4382-x.

Acute exacerbations of progressive-fibrosing interstitial lung diseases.

Kolb M, Bondue B, Pesci A, et al.

European respiratory review : an official journal of the European Respiratory Society 2018; (27(150)) doi:10.1183/16000617.0071-2018.

Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases.

Swigris JJ, Brown KK, Abdulqawi R, et al.

European respiratory review : an official journal of the European Respiratory Society 2018; (27(150)) doi:10.1183/16000617.0075-2018.

Interstitial Pneumonia with Autoimmune Features.

Graney BA, Fischer A

Annals of the American Thoracic Society 2019; (16(5)):525-533 doi:10.1513/AnnalsATS.201808-565CME.

Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey.

Lim RK, Humphreys C, Morisset J, et al.

The European respiratory journal 2019; (54(2)) doi:10.1183/13993003.00421-2019.

The Effect of Pulmonary Rehabilitation on Non-chronic Obstructive Pulmonary Disease Patients.

Rokach A, Romem A, Arish N, et al.

The Israel Medical Association journal : IMAJ 2019; (21(5)):326-329.

Autoantibodies in interstitial lung diseases.

Stevenson BR, Thompson GA, Watson MC, et al.

Pathology 2019; (51(5)):518-523 doi:10.1016/j.pathol.2019.03.007.

Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis.

Tsuji H, Nakashima R, Hosono Y, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2020; (72(3)):488-498 doi:10.1002/art.41105.

Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.

Motegi SI, Sekiguchi A, Toki S, et al.

European journal of dermatology : EJD 2019; (29(5)):511-517 doi:10.1684/ejd.2019.3634.

The Role of Palliative Care in Reducing Symptoms and Improving Quality of Life for Patients with Idiopathic Pulmonary Fibrosis: A Review.

Zou RH, Kass DJ, Gibson KF, Lindell KO

Pulmonary therapy 2020; (6(1)):35-46 doi:10.1007/s41030-019-00108-2.

Predictors of progression in systemic sclerosis patients with interstitial lung disease.

Distler O, Assassi S, Cottin V, et al.

The European respiratory journal 2020; (55(5)) doi:10.1183/13993003.02026-2019.

Diagnostic approach of fibrosing interstitial lung diseases of unknown origin.

Cottin V, Valenzuela C

Presse medicale (Paris, France : 1983) 2020; (49(2)):104021 doi:10.1016/j.lpm.2020.104021.

The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3.6-Year Prospective Study from a Referral Center of Interstitial Lung Disease and Lung Transplantation.

Atienza-Mateo B, Remuzgo-Martínez S, Mora Cuesta VM, et al.

Journal of clinical medicine 2020; (9(6)) doi:10.3390/jcm9061606.

Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases.

Ghembaza A, Vautier M, Cacoub P, et al.

Chest 2020; (158(6)):2323-2332 doi:10.1016/j.chest.2020.05.558.

Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease.

Romero-Bueno F, Diaz Del Campo P, Trallero-Araguás E, et al.

Seminars in arthritis and rheumatism 2020; (50(4)):776-790 doi:10.1016/j.semarthrit.2020.03.007.

Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease.

Boerner EB, Cuyas M, Theegarten D, et al.

Respiration; international review of thoracic diseases 2020; (99(8)):628-636 doi:10.1159/000508540.

Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline.

Jacobs SS, Krishnan JA, Lederer DJ, et al.

American journal of respiratory and critical care medicine 2020; (202(10)):e121-e141 doi:10.1164/rccm.202009-3608ST.

Clinical characteristics of anti-MDA5 antibody-positive interstitial lung disease.

Kaenmuang P, Navasakulpong A

Respirology case reports 2021; (9(1)):e00701 doi:10.1002/rcr2.701.

Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential.

Sebastiani M, Faverio P, Manfredi A, et al.

Biomedicines 2020; (9(1)) doi:10.3390/biomedicines9010017.

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.

Cottin V, Richeldi L, Rosas I, et al.

Respiratory research 2021; (22(1)):84 doi:10.1186/s12931-021-01668-1.

Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody.

Kamiya H, Panlaqui OM

BMJ open 2021; (11(3)):e040465 doi:10.1136/bmjopen-2020-040465.

Clinical characteristics of interstitial lung diseases positive to different anti-synthetase antibodies.

Jiang M, Dong X, Zheng Y

Medicine 2021; (100(19)):e25816 doi:10.1097/MD.0000000000025816.

High-Resolution CT Findings of Myositis-Related Interstitial Lung Disease.

Egashira R

Medicina (Kaunas, Lithuania) 2021; (57(7)) doi:10.3390/medicina57070692.

Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders.

Kuwana M, Gil-Vila A, Selva-O'Callaghan A

Therapeutic advances in musculoskeletal disease 2021; (13()):1759720X211032457 doi:10.1177/1759720X211032457.

Exacerbation of connective tissue disease-associated interstitial lung disease due to influenza vaccination.

Okusaki T, Fukuhara K

Respiratory medicine case reports 2021; (33()):101463 doi:10.1016/j.rmcr.2021.101463.

Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders.

Panagopoulos P, Goules A, Hoffmann-Vold AM, et al.

Therapeutic advances in musculoskeletal disease 2021; (13()):1759720X211037519 doi:10.1177/1759720X211037519.

Fibrotic interstitial lung disease - palliative care needs: a World-Café qualitative study.

Cassidy N, Fox L, Love M, et al.

BMJ supportive & palliative care 2024; (14(e3)):e2649-e2656 doi:10.1136/bmjspcare-2021-003249.

Acute exacerbation of interstitial lung disease associated with rheumatic disease.

Luppi F, Sebastiani M, Salvarani C, et al.

Nature reviews. Rheumatology 2022; (18(2)):85-96 doi:10.1038/s41584-021-00721-z.

[Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury].

Zhang PL, Yang HX, Zhang LN, et al.

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 2021; (53(6)):1055-1060.

Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review.

McPherson M, Economidou S, Liampas A, et al.

Seminars in arthritis and rheumatism 2022; (53()):151959 doi:10.1016/j.semarthrit.2022.151959.

Pathogenesis of Anti-melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis: A Concise Review With an Emphasis on Type I Interferon System.

Hu H, Yang H, Liu Y, Yan B

Frontiers in medicine 2021; (8()):833114 doi:10.3389/fmed.2021.833114.

Syndecan-2 regulates PAD2 to exert antifibrotic effects on RA-ILD fibroblasts.

Tsoyi K, Esposito AJ, Sun B, et al.

Scientific reports 2022; (12(1)):2847 doi:10.1038/s41598-022-06678-7.

Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.

Matteson EL, Kelly C, Distler JHW, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2022; (74(6)):1039-1047 doi:10.1002/art.42075.

Interstitial Pneumonia with Autoimmune Features: What the Rheumatologist Needs to Know.

Joerns EK, Adams TN, Sparks JA, et al.

Current rheumatology reports 2022; (24(6)):213-226 doi:10.1007/s11926-022-01072-8.

Identification and Prognosis of Patients With Interstitial Pneumonia With Autoimmune Features.

Jiwrajka N, Loizidis G, Patterson KC, et al.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2022; (28(5)):257-264 doi:10.1097/RHU.0000000000001847.

Immunomodulatory treatment of interstitial lung disease.

van den Bosch L, Luppi F, Ferrara G, Mura M

Therapeutic advances in respiratory disease 2022; (16()):17534666221117002 doi:10.1177/17534666221117002.

The Role of Myositis-Specific Autoantibodies and the Management of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: A Systematic Review.

Teel A, Lu J, Park J, et al.

Seminars in arthritis and rheumatism 2022; (57()):152088 doi:10.1016/j.semarthrit.2022.152088.

Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China.

Wang R, Zhao Y, Qi F, et al.

Clinical rheumatology 2023; (42(3)):703-709 doi:10.1007/s10067-022-06404-8.

CT predictors of outcomes in patients with connective tissue disease and progressive lung fibrosis.

Shou AY, Salvatore MM

Clinical imaging 2023; (94()):42-49 doi:10.1016/j.clinimag.2022.11.022.

Interstitial Lung Disease: A Focused Review for the Emergency Clinician.

Constantino K, Gottlieb M, Long B

The Journal of emergency medicine 2023; (64(2)):156-166 doi:10.1016/j.jemermed.2022.10.015.

Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial.

Matteson EL, Aringer M, Burmester GR, et al.

Clinical rheumatology 2023; (42(9)):2311-2319 doi:10.1007/s10067-023-06623-7.

Predictive factors for anti-MDA5 antibody in patients with dermatomyositis: a retrospective multicenter study.

Castellanos-Gonzalez M, Bris BB, Marsol IB, et al.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2023; (21(7)):741-748 doi:10.1111/ddg.15089.

Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.

Mankikian J, Caille A, Reynaud-Gaubert M, et al.

The European respiratory journal 2023; (61(6)) doi:10.1183/13993003.02071-2022.

Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease.

Higuero Sevilla JP, Memon A, Hinchcliff M

Arthritis research & therapy 2023; (25(1)):118 doi:10.1186/s13075-023-03090-y.

Myositis-associated interstitial lung disease.

Vu TTT, Brown KK, Solomon JJ

Current opinion in pulmonary medicine 2023; (29(5)):427-435 doi:10.1097/MCP.0000000000001000.

New therapies in anti-MDA5 antibody-positive dermatomyositis.

Yasui M, Iwamoto T, Furuta S

Current opinion in rheumatology 2024; (36(1)):61-68 doi:10.1097/BOR.0000000000000979.

Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.

Raghu G, Montesi SB, Silver RM, et al.

American journal of respiratory and critical care medicine 2024; (209(2)):137-152 doi:10.1164/rccm.202306-1113ST.

Mycophenolate mofetil versus cyclophosphamide plus in patients with connective tissue disease-associated interstitial lung disease: Efficacy and safety analysis.

Wang P, Zhang L, Guo Q, et al.

Open medicine (Warsaw, Poland) 2023; (18(1)):20230838 doi:10.1515/med-2023-0838.

Antibody predictors of mortality and lung function trends in myositis spectrum interstitial lung disease.

Hannah JR, Lawrence A, Martinovic J, et al.

Rheumatology (Oxford, England) 2024; (63(11)):3080-3090 doi:10.1093/rheumatology/kead638.

Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study.

Ji Q, Pan W, Zhang D, et al.

Frontiers in immunology 2023; (14()):1237209 doi:10.3389/fimmu.2023.1237209.

Progressive Pulmonary Fibrosis: Where Are We Now?

Kang HK, Song JW

Tuberculosis and respiratory diseases 2024; (87(2)):123-133 doi:10.4046/trd.2023.0119.

A Case of Dermatomyositis with Coexistence of Positive Anti-MDA5 Antibodies and Anti-SSA/RO52 Antibodies, Combined with Necrotic Skin Ulcers.

Sun T, Hu ZH, He JS, et al.

International medical case reports journal 2024; (17()):9-15 doi:10.2147/IMCRJ.S441691.

Lung imaging patterns in connective tissue disease-associated interstitial lung disease impact prognosis and immunosuppression response.

Zheng B, Marinescu DC, Hague CJ, et al.

Rheumatology (Oxford, England) 2024; (63(10)):2734-2740 doi:10.1093/rheumatology/keae076.

Interstitial Lung Disease: A Review.

Maher TM

JAMA 2024; (331(19)):1655-1665 doi:10.1001/jama.2024.3669.

A Review of Antisynthetase Syndrome-Associated Interstitial Lung Disease.

Patel P, Marinock JM, Ajmeri A, Brent LH

International journal of molecular sciences 2024; (25(8)) doi:10.3390/ijms25084453.

Review of Pulmonary Manifestations in Antisynthetase Syndrome.

Ghanbar MI, Danoff SK

Seminars in respiratory and critical care medicine 2024; (45(3)):365-385 doi:10.1055/s-0044-1785536.

Imaging in the diagnosis and management of fibrosing interstitial lung diseases.

Lederer C, Storman M, Tarnoki AD, et al.

Breathe (Sheffield, England) 2024; (20(1)):240006 doi:10.1183/20734735.0006-2024.

Prognostic analysis of MDA5-associated clinically amyopathic dermatomyositis with interstitial lung disease.

Wang W, Sun X, Xu Y, et al.

Immunity, inflammation and disease 2024; (12(6)):e1332 doi:10.1002/iid3.1332.

Identification and management of interstitial lung disease associated with systemic sclerosis (SSc-ILD), rheumatoid arthritis (RA-ILD), and polymyositis/dermatomyositis (PM/DM-ILD): development of expert consensus-based clinical algorithms.

Kondoh Y, Bando M, Kawahito Y, et al.

Expert review of respiratory medicine 2024; (18(6)):447-456 doi:10.1080/17476348.2024.2374910.

2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.

Johnson SR, Bernstein EJ, Bolster MB, et al.

Arthritis care & research 2024; (76(8)):1070-1082 doi:10.1002/acr.25347.

2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.

Johnson SR, Bernstein EJ, Bolster MB, et al.

Arthritis care & research 2024; (76(8)):1051-1069 doi:10.1002/acr.25348.

Antifibrotic therapy in progressive pulmonary fibrosis: a review of recent advances.

Naqvi M, Hannah J, Lawrence A, et al.

Expert review of respiratory medicine 2024; (18(6)):397-407 doi:10.1080/17476348.2024.2375420.

Asymptomatic and slowly progressive anti-MDA5 ILD: A report of three cases deviating from a notoriously rapidly progressive ILD.

Puthumana RM, Koch AL, Schettino C, Vehar SJ

Respiratory medicine case reports 2024; (51()):102072 doi:10.1016/j.rmcr.2024.102072.

Value of bronchoalveolar lavage fluid metagenomic next-generation sequencing in acute exacerbation of fibrosing interstitial lung disease: an individualized treatment protocol based on microbiological evidence.

Zhan S, Li S, Cao Y, et al.

BMC pulmonary medicine 2024; (24(1)):400 doi:10.1186/s12890-024-03216-1.

Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-Associated Interstitial Lung Disease Subtypes.

McDermott GC, Hayashi K, Juge PA, et al.

Arthritis care & research 2025; (77(2)):185-194 doi:10.1002/acr.25432.

Treatment of rheumatoid arthritis-associated interstitial lung disease: An appraisal of the 2023 ACR/CHEST guideline.

Saavedra AA, Mueller KT, Kowalski EN, et al.

Current treatment options in rheumatology 2024; (10(4)):43-60 doi:10.1007/s40674-024-00217-3.

Clinical Characteristics and Outcomes of Patients with Anti-MDA5 Antibody Associated Rapidly Progressive Interstitial Lung Disease (RP-ILD): A Case Series.

Gangadharan H, Seetha AP, Musthafa S, et al.

Mediterranean journal of rheumatology 2024; (35(4)):668-679 doi:10.31138/mjr.020324.cco.

Validation of a semi-quantitative method to assess interstitial lung disease severity and progression in systemic sclerosis by standard and low-dose HRCT scans.

Tschalèr L, Jordan S, Aaløkken TM, et al.

RMD open 2025; (11(1)) doi:10.1136/rmdopen-2024-004938.

Total lung capacity is predictive of disease severity and survival in systemic sclerosis: A longitudinal analysis in 2347 patients from the French National Cohort Study.

Chaigne B, Bense A, Aubourg F, et al.

Journal of autoimmunity 2025; (152()):103391 doi:10.1016/j.jaut.2025.103391.

Development of a prediction model for progression of rheumatoid arthritis-associated interstitial lung disease using serologic and clinical factors: The prospective KORAIL cohort.

Chang SH, Paudel ML, McDermott GC, et al.

Seminars in arthritis and rheumatism 2025; (73()):152729 doi:10.1016/j.semarthrit.2025.152729.

Procalcitonin in acute exacerbation of interstitial lung disease: A systematic review of current evidence.

Srivali N, De Giacomi F

Heart & lung : the journal of critical care 2025; (73()):221-227 doi:10.1016/j.hrtlng.2025.05.014.

[Connective tissue disease-associated interstitial lung diseases : A pattern-based approach to diagnosis].

Mura R, Kifjak D, Kastrati K, et al.

Radiologie (Heidelberg, Germany) 2025; (65(10)):734-747 doi:10.1007/s00117-025-01492-4.

ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease.

Antoniou KM, Distler O, Gheorghiu AM, et al.

The European respiratory journal 2026; (67(1)) doi:10.1183/13993003.02533-2024.

High-Resolution CT Findings in Interstitial Lung Disease Associated with Connective Tissue Diseases: Differentiating Patterns for Clinical Practice-A Systematic Review with Meta-Analysis.

Drimus JC, Duma RC, Trăilă D, et al.

Journal of clinical medicine 2025; (14(17)) doi:10.3390/jcm14176164.

Longitudinal change of idiopathic inflammatory myopathy-associated interstitial lung disease on high-resolution computed tomography, a prospective cohort study.

Qiang Y, Wang H, Ni Y, et al.

BMC pulmonary medicine 2025; (25(1)):503 doi:10.1186/s12890-025-03962-w.

The importance of considering progression speed in systemic sclerosis-associated interstitial lung diseases: application of 2022 and 2024 clinical practice guidelines for progressive pulmonary fibrosis, a retrospective cohort study.

Roeser A, Brillet PY, Tran Ba S, et al.

Respiratory research 2025; (26(1)):305 doi:10.1186/s12931-025-03375-7.

Distinct phenotypes and prognosis between Jo-1 and non-Jo-1 subtypes in anti-synthetase syndrome: a retrospective cohort study from China.

Zhang X, Wang L, Cheng Q, et al.

Clinical rheumatology 2026; (45(2)):1199-1207 doi:10.1007/s10067-025-07849-3.

Acute Hypoxemic Respiratory Failure Caused by Nonspecific Interstitial Pneumonia in Mixed Connective Tissue Disease: A Case Report.

Naqvi SM, Nadeem AUR, Liu J, et al.

Cureus 2025; (17(12)):e99922 doi:10.7759/cureus.99922.

Consensus Document on the Multidisciplinary Management of Advanced-Stage Respiratory Diseases.

de Miguel-Díez J, Castillo-Padrós M, Figueira-Gonçalves JM, et al.

Archivos de bronconeumologia 2026; (62(7)):481-498 doi:10.1016/j.arbres.2026.01.014.

Checkerboard Hyperkeratosis With Apoptotic Keratinocytes as Features of Mechanic's Hands and Review of the Literature.

Long V, Joel LHL

The American Journal of dermatopathology 2026; (48(4)):278-282 doi:10.1097/DAD.0000000000003231.

Clinical and radiological distinctiveness of anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis-associated interstitial lung disease: a retrospective cohort study.

Han Y, Jiang F, Zhu Q, et al.

Scandinavian journal of rheumatology 2026; (55(5)):315-322 doi:10.1080/03009742.2026.2650907.

Rheumatoid arthritis-associated interstitial lung disease: Pathogenesis, risk stratification, and management.

Gao R, Liu S, Song L

Respiratory medicine 2026; (261()):109066 doi:10.1016/j.rmed.2026.109066.

Contemporary Guideline Perspectives on Methotrexate and Biologic/Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Yamakawa H, Yokosawa M

Internal medicine (Tokyo, Japan) 2026; doi:10.2169/internalmedicine.8144-26.

Psychological Distress and Quality of Life in Fibrotic Interstitial Lung Diseases: A Real-World Observational Study.

Moura MJ, Sousa M, Fernandes AL, et al.

Acta medica portuguesa 2026; (39(9)):539-543 doi:10.20344/amp.24629.

Patient-physician communication and shared decision-making in interstitial lung disease care: A mixed-method study based on a patient community survey.

Sugino K, Kinoshita Y, Fukai Y, et al.

Respiratory investigation 2026; (64(6)):101519 doi:10.1016/j.resinv.2026.101519.

Occurrence of progressive pulmonary fibrosis and its association with survival in connective tissue disease-associated interstitial lung disease: an international retrospective cohort study.

Guiot J, Teitsma XM, Dimitroulas T, et al.

Rheumatology international 2026; (46(10)).

High-resolution computed tomography assessment of connective tissue disease-associated interstitial lung disease: Advances in diagnosis and prognostic evaluation.

Jiang SY, Su KX, Pang CF, et al.

World journal of radiology 2026; (18(9)):125041 doi:10.4329/wjr.125041.

Divergent approaches to rheumatoid arthritis-associated interstitial lung disease: a comparative analysis of international clinical practice guidelines.

Garcia-Salinas R, Chávez-Lopez M, Gómez RA, et al.

Rheumatology international 2026; (46(11)).